{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:48:58Z","timestamp":1768416538694,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T00:00:00Z","timestamp":1251849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-244x-9-54","type":"journal-article","created":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T18:14:32Z","timestamp":1251915272000},"source":"Crossref","is-referenced-by-count":35,"title":["Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia"],"prefix":"10.1186","volume":"9","author":[{"given":"Douglas E","family":"Faries","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haya","family":"Ascher-Svanum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen W","family":"Nyhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce J","family":"Kinon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,2]]},"reference":[{"issue":"Suppl","key":"602_CR1","doi-asserted-by":"publisher","first-page":"s64","DOI":"10.1192\/bjp.191.50.s64","volume":"50","author":"S Hamer","year":"2007","unstructured":"Hamer S, Haddad PM: Adverse effects of antipsychotics as outcome measures. Br J Psychiatry. 2007, 50 (Suppl): s64-s70. 10.1192\/bjp.191.50.s64.","journal-title":"Br J Psychiatry"},{"key":"602_CR2","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056\/NEJMoa051688.","journal-title":"N Engl J Med"},{"key":"602_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1741-7015-3-21","volume":"3","author":"H Liu-Seifert","year":"2005","unstructured":"Liu-Seifert H, Adams DH, Kinon BJ: Discontinuation of treatment of schizophrenia patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005, 3: 21-10.1186\/1741-7015-3-21.","journal-title":"BMC Med"},{"issue":"Suppl 2","key":"602_CR4","first-page":"28","volume":"62","author":"MR Dossenbach","year":"2001","unstructured":"Dossenbach MR, Kratky P, Schneidman M, Grundy SL, Metcalfe S, Tollefson GD, Belmaker RH: Evidence for the effectiveness of olanzapine among patients nonresponsive and\/or intolerant to risperidone. J Clin Psychiatry. 2001, 62 (Suppl 2): 28-34.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 14","key":"602_CR5","first-page":"4","volume":"68","author":"JP McEvoy","year":"2007","unstructured":"McEvoy JP: The costs of schizophrenia. J Clin Psychiatry. 2007, 68 (Suppl 14): 4-7.","journal-title":"J Clin Psychiatry"},{"key":"602_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1192\/bjp.187.2.137","volume":"187","author":"S Park","year":"2005","unstructured":"Park S, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB: Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. Br J Psychiatry. 2005, 187: 137-142. 10.1192\/bjp.187.2.137.","journal-title":"Br J Psychiatry"},{"key":"602_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","volume":"164","author":"TS Stroup","year":"2007","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK, CATIE Investigators: Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007, 164: 415-427. 10.1176\/appi.ajp.164.3.415.","journal-title":"Am J Psychiatry"},{"key":"602_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","volume":"163","author":"TS Stroup","year":"2006","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, CATIE Investigators: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006, 163: 611-622. 10.1176\/appi.ajp.163.4.611.","journal-title":"Am J Psychiatry"},{"key":"602_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/0269881105056668","volume":"20","author":"PJ Weiden","year":"2006","unstructured":"Weiden PJ: Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol. 2006, 20: 104-118. 10.1177\/0269881105056668.","journal-title":"J Psychopharmacol"},{"issue":"Suppl 4","key":"602_CR10","first-page":"34","volume":"68","author":"PJ Weiden","year":"2007","unstructured":"Weiden PJ: Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry. 2007, 68 (Suppl 4): 34-39.","journal-title":"J Clin Psychiatry"},{"key":"602_CR11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4088\/JCP.v64n0514","volume":"64","author":"PJ Weiden","year":"2003","unstructured":"Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL: Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003, 64: 580-588.","journal-title":"J Clin Psychiatry"},{"key":"602_CR12","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1176\/ajp.2006.163.12.2090","volume":"163","author":"SM Essock","year":"2006","unstructured":"Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA: Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006, 163: 2090-2095. 10.1176\/appi.ajp.163.12.2090.","journal-title":"Am J Psychiatry"},{"key":"602_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1524-4733.2006.00083.x","volume":"9","author":"SL Tunis","year":"2006","unstructured":"Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R: Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health. 2006, 9: 77-89. 10.1111\/j.1524-4733.2006.00083.x.","journal-title":"Value Health"},{"key":"602_CR14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised. 2000, Washington, DC: American Psychiatric Association"},{"key":"602_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep. 1962, 10: 799-812.","journal-title":"Psychol Rep"},{"key":"602_CR16","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR, Rubin DB: Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984, 79: 516-524. 10.2307\/2288398.","journal-title":"J Am Stat Assoc"},{"key":"602_CR17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1197\/j.aem.2004.02.530","volume":"11","author":"CD Newgard","year":"2004","unstructured":"Newgard CD, Hedges JR, Arthur M, Mullins RJ: Advanced statistics: the propensity score--a method for estimating treatment effect in observational research. Acad Emerg Med. 2004, 11: 953-961.","journal-title":"Acad Emerg Med"},{"key":"602_CR18","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, L\u00f3pez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-R\u00f6ssler A, Grobbee DE, EUFEST study group: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008, 371: 1085-1097. 10.1016\/S0140-6736(08)60486-9.","journal-title":"Lancet"},{"key":"602_CR19","volume-title":"Poster presented at: the 47th New Clinical Drug Evaluation Unit (from Annual Conference of National Institute of Mental Health); June 11-14","author":"D Faries","year":"2007","unstructured":"Faries D, Obenchain R, Nyhuis A, Ascher-Svanum H: Concerns with common methods for cost comparisons: addressing issues with log transformations and pre post analyses. Poster presented at: the 47th New Clinical Drug Evaluation Unit (from Annual Conference of National Institute of Mental Health); June 11-14. 2007, ; Boca Raton, FL"},{"key":"602_CR20","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJM199409083311006","volume":"331","author":"SB Soumerai","year":"1994","unstructured":"Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P: Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994, 331: 650-655. 10.1056\/NEJM199409083311006.","journal-title":"N Engl J Med"},{"key":"602_CR21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1176\/ps.2007.58.7.983","volume":"58","author":"J Kreyenbuhl","year":"2007","unstructured":"Kreyenbuhl J, Marcus SC, West JC, Wilk J, Olfson M: Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv. 2007, 58: 983-990. 10.1176\/appi.ps.58.7.983.","journal-title":"Psychiatr Serv"},{"key":"602_CR22","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.290.12.1624","volume":"290","author":"SR Tunis","year":"2003","unstructured":"Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003, 290: 1624-1632. 10.1001\/jama.290.12.1624.","journal-title":"JAMA"},{"key":"602_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","volume":"101","author":"JM Meyer","year":"2008","unstructured":"Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA: Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008, 101: 273-286. 10.1016\/j.schres.2007.12.487.","journal-title":"Schizophr Res"},{"key":"602_CR24","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1345\/aph.1C470","volume":"37","author":"LD Ried","year":"2003","unstructured":"Ried LD, Renner BT, Bengtson MA, Wilcox BM, Acholonu WW: Weight change after an atypical antipsychotic switch. Ann Pharmacother. 2003, 37: 1381-1386. 10.1345\/aph.1C470.","journal-title":"Ann Pharmacother"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-9-54\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-9-54.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-9-54","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-9-54.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T07:11:59Z","timestamp":1710573119000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-9-54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-9-54","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,2]]},"article-number":"54"}}